449 related articles for article (PubMed ID: 33429304)
1. Factors influencing patients' willingness-to-pay for disease-modifying therapies for multiple sclerosis.
Poudel N; Banjara B; Kamau S; Frost N; Ngorsuraches S
Mult Scler Relat Disord; 2021 Feb; 48():102720. PubMed ID: 33429304
[TBL] [Abstract][Full Text] [Related]
2. Patients' preferences and willingness-to-pay for disease-modifying therapies.
Frost N; Freeman J; Brixner D; Mort J; Clem J; Ngorsuraches S
Mult Scler Relat Disord; 2019 Oct; 35():55-60. PubMed ID: 31323483
[TBL] [Abstract][Full Text] [Related]
3. The Impact of Disease-Modifying Therapy Access Barriers on People With Multiple Sclerosis: Mixed-Methods Study.
Simacek KF; Ko JJ; Moreton D; Varga S; Johnson K; Katic BJ
J Med Internet Res; 2018 Oct; 20(10):e11168. PubMed ID: 30377144
[TBL] [Abstract][Full Text] [Related]
4. Real-world disease-modifying therapy usage in persons with relapsing-remitting multiple sclerosis: Cross-sectional data from the Swiss Multiple Sclerosis Registry.
Bossart J; Kamm CP; Kaufmann M; Stanikić M; Puhan MA; Kesselring J; Zecca C; Gobbi C; Rapold I; Kurmann R; Ammann S; von Wyl V;
Mult Scler Relat Disord; 2022 Apr; 60():103706. PubMed ID: 35228114
[TBL] [Abstract][Full Text] [Related]
5. Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis.
Neuberger EE; Abbass IM; Jones E; Engmann NJ
Neurol Ther; 2021 Jun; 10(1):183-196. PubMed ID: 33244713
[TBL] [Abstract][Full Text] [Related]
6. Health insurance affects the use of disease-modifying therapy in multiple sclerosis.
Wang G; Marrie RA; Salter AR; Fox R; Cofield SS; Tyry T; Cutter GR
Neurology; 2016 Jul; 87(4):365-74. PubMed ID: 27358338
[TBL] [Abstract][Full Text] [Related]
7. The Impact of Patient Support Programs on Adherence to Disease-Modifying Therapies of Patients with Relapsing-Remitting Multiple Sclerosis in Germany: A Non-Interventional, Prospective Study.
Lenz F; Harms L
Adv Ther; 2020 Jun; 37(6):2999-3009. PubMed ID: 32333326
[TBL] [Abstract][Full Text] [Related]
8. Disease-Modifying Therapy Adherence and Associated Factors in a National Sample of Medicare Patients With Multiple Sclerosis.
Li P; Ladage VP; Berger J; Chahin S; Jhaveri M; Geremakis C; Doshi JA
Value Health; 2020 Mar; 23(3):328-334. PubMed ID: 32197728
[TBL] [Abstract][Full Text] [Related]
9. Patients experiences with multiple sclerosis disease-modifying therapies in daily life - a qualitative interview study.
Sippel A; Riemann-Lorenz K; Scheiderbauer J; Kleiter I; Morrison R; Kofahl C; Heesen C
BMC Health Serv Res; 2021 Oct; 21(1):1141. PubMed ID: 34686166
[TBL] [Abstract][Full Text] [Related]
10. Treatment Patterns and Relapses Among Newly Treated Multiple Sclerosis Patients From a Retrospective Claims Analysis.
Kantor D; Mehta R; Pelletier C; Tian M; Noxon V; Johnson BH; Bonafede M
Clin Ther; 2020 Nov; 42(11):2136-2147.e3. PubMed ID: 33160682
[TBL] [Abstract][Full Text] [Related]
11. Patient perspective on decisions to switch disease-modifying treatments in relapsing-remitting multiple sclerosis.
Manzano A; Eskyté I; Ford HL; Pavitt SH; Potrata B; Schmierer K; Chataway J; Webb EJD; Meads D; Pepper G; Bekker HL
Mult Scler Relat Disord; 2020 Nov; 46():102507. PubMed ID: 32979733
[TBL] [Abstract][Full Text] [Related]
12. Disease modifying therapies continue to drive up health care cost among individuals with multiple sclerosis.
Kim Y; Krause TM; Blum P; Freeman L
Mult Scler Relat Disord; 2019 May; 30():69-75. PubMed ID: 30738875
[TBL] [Abstract][Full Text] [Related]
13. Treatment patterns and persistence on disease modifying therapies for multiple sclerosis and its associated factors.
Cárdenas-Robledo S; Arenas-Vargas LE; Arenas RD; Gaspar-Toro JM; Muñoz-Rosero ÁM; Tafur-Borrero AH; Marín-Medina DS; Acosta-Fajardo HA; Guío-Sánchez C; López-Reyes L
BMC Neurol; 2024 Apr; 24(1):108. PubMed ID: 38566012
[TBL] [Abstract][Full Text] [Related]
14. Disparities in DMT treatment: Demographic and neurocognitive differences between MS patients currently treated versus not treated with disease-modifying therapies.
Leavitt VM; Dworkin JD; Galioto R; Ratzan AS
Mult Scler Relat Disord; 2024 May; 85():105508. PubMed ID: 38452646
[TBL] [Abstract][Full Text] [Related]
15. Treatment Patterns Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy.
Bowen J; Mehta R; Pelletier C; Tian M; Noxon V; Johnson BH; Bonafede M
Adv Ther; 2020 Jul; 37(7):3163-3177. PubMed ID: 32436028
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of drivers of treatment switch in relapsing multiple sclerosis: a study from the Italian MS Registry.
Iaffaldano P; Lucisano G; Guerra T; Patti F; Cocco E; De Luca G; Brescia Morra V; Pozzilli C; Zaffaroni M; Ferraro D; Gasperini C; Salemi G; Bergamaschi R; Lus G; Inglese M; Romano S; Bellantonio P; Di Monte E; Maniscalco GT; Conte A; Lugaresi A; Vianello M; Torri Clerici VLA; Di Sapio A; Pesci I; Granella F; Totaro R; Marfia GA; Danni MC; Cavalla P; Valentino P; Aguglia U; Montepietra S; Ferraro E; Protti A; Spitaleri D; Avolio C; De Riz M; Maimone D; Cavaletti G; Gazzola P; Tedeschi G; Sessa M; Rovaris M; Di Palma F; Gatto M; Cargnelutti D; De Robertis F; Logullo FO; Rini A; Meucci G; Ardito B; Banfi P; Nasuelli D; Paolicelli D; Rocca MA; Portaccio E; Chisari CG; Fenu G; Onofrj M; Carotenuto A; Ruggieri S; Tortorella C; Ragonese P; Nica M; Amato MP; Filippi M; Trojano M;
J Neurol; 2024 Mar; 271(3):1150-1159. PubMed ID: 38135850
[TBL] [Abstract][Full Text] [Related]
17. Adherence to Disease-Modifying Therapies for Multiple Sclerosis.
Higuera L; Carlin CS; Anderson S
J Manag Care Spec Pharm; 2016 Dec; 22(12):1394-1401. PubMed ID: 27882830
[TBL] [Abstract][Full Text] [Related]
18. Clinical course and outcome of SARS-CoV-2 infection in multiple sclerosis patients treated with disease-modifying therapies - the Polish experience.
Czarnowska A; Brola W; Zajkowska O; Rusek S; Adamczyk-Sowa M; Kubicka-Bączyk K; Kalinowska-Łyszczarz A; Kania K; Słowik A; Wnuk M; Marona M; Podlecka-Piętowska A; Nojszewska M; Zakrzewska-Pniewska B; Jasińska E; Gołuch K; Lech B; Noga M; Perenc A; Popiel M; Lasek-Bal A; Puz P; Maciejowska K; Kucharska-Lipowska M; Lipowski M; Kapica-Topczewska K; Chorąży M; Tarasiuk J; Kochanowicz J; Kulikowska J; Wawrzyniak S; Niezgodzińska-Maciejek A; Pokryszko-Dragan A; Gruszka E; Budrewicz S; Białek M; Kurkowska-Jastrzębska I; Kurowska K; Stępień A; Włodek A; Ptasznik V; Pawełczyk M; Sobolewski P; Lejmel H; Strzalińska K; Maciejowski M; Tutaj A; Zwiernik J; Litwin A; Lewańczyk B; Paprocka I; Zwiernik B; Pawlos A; Borysowicz A; Narożnik A; Michałowska A; Nosek K; Fudala M; Milewska-Jędrzejczak M; Kułakowska A; Bartosik-Psujek H
Neurol Neurochir Pol; 2021; 55(2):212-222. PubMed ID: 33856686
[TBL] [Abstract][Full Text] [Related]
19. Teriflunomide vs injectable disease modifying therapies for relapsing forms of MS.
Vermersch P; Oh J; Cascione M; Oreja-Guevara C; Gobbi C; Travis LH; Myhr KM; Coyle PK
Mult Scler Relat Disord; 2020 Aug; 43():102158. PubMed ID: 32470857
[TBL] [Abstract][Full Text] [Related]
20. Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes.
Yano H; Gonzalez C; Healy BC; Glanz BI; Weiner HL; Chitnis T
Mult Scler Relat Disord; 2019 Oct; 35():119-127. PubMed ID: 31374460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
